46
Views
4
CrossRef citations to date
0
Altmetric
Research Article

A Prospective, Randomized, Multicenter Comparative Study of Clinafloxacin Versus a Ceftriaxone-based Regimen in the Treatment of Hospitalized Patients with Community-acquired Pneumonia

Pages 832-837 | Published online: 08 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

João Paulo Telles, Juliette Cieslinski, Juliano Gasparetto & Felipe Francisco Tuon. (2019) Efficacy of Ceftriaxone 1 g daily Versus 2 g daily for The Treatment of Community-Acquired Pneumonia: A Systematic Review with Meta-Analysis. Expert Review of Anti-infective Therapy 17:7, pages 501-510.
Read now

Articles from other publishers (3)

Peter K. Kurotschka, Michelle Bentivegna, Cassie Hulme & Mark H. Ebell. (2024) Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis. Journal of General Internal Medicine.
Crossref
Jörg Ruhe & Donna Mildvan. (2013) Does Empirical Therapy with a Fluoroquinolone or the Combination of a β-Lactam Plus a Macrolide Result in Better Outcomes for Patients Admitted to the General Ward?. Infectious Disease Clinics of North America 27:1, pages 115-132.
Crossref
Chaker Ben Salem, Neila Fathallah, Houssem Hmouda & Kamel Bouraoui. (2011) Drug-Induced Hypoglycaemia. Drug Safety 34:1, pages 21-45.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.